文献速递血栓与止血

达比加群酯在儿童静脉血栓中的IIa期研究:药代动力学、安全性与耐受性

Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability.
PubMed 文献 · J Thromb Haemost · 2017-10-26

这项开放标签、单臂IIa期研究纳入18例1至<12岁静脉血栓患儿,按年龄和体重列线图给予达比加群酯口服液。药代动力学-药效学关系与成人相似,ECT和dTT呈线性、APTT呈非线性;未报告严重不良事件、出血事件或复发性静脉血栓。

要点

  • 达比加群酯口服液在1至<12岁静脉血栓患儿中的药代动力学-药效学关系与成人相似。
  • 研究期间未报告严重不良事件、出血事件或复发性静脉血栓。
  • 单次给药组3例(筛选期)和多次给药组1例(治疗期)报告轻度不良事件。

核心结论

  • 本研究支持在静脉血栓患儿中进一步评估达比加群酯口服液。

研究设计与样本

  • 开放标签、单臂IIa期研究,纳入18例已完成低分子量肝素或口服抗凝药计划治疗的静脉血栓患儿,分2至<12岁和1至<2岁两组。
  • 患儿按年龄和体重调整的列线图接受达比加群酯口服液,原计划每日两次给药3天,后方案修改为第1天单次给药。
  • 主要终点为药代动力学/药效学相关指标,安全性终点包括出血事件及所有其他不良事件的发生率。

主要发现

  • 18例患儿接受的达比加群酯口服液暴露量相当于成人150 mg每日两次的剂量。
  • 预测的达比加群稳态谷浓度在儿童与成人之间基本相当。
  • 药代动力学/药效学关系在ECT和dTT呈线性,在APTT呈非线性。
  • 未报告严重或重度不良事件、出血事件或复发性静脉血栓。
  • 单次给药组3例(筛选期)和多次给药组1例(治疗期)报告轻度不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Dabigatran etexilate may provide a new treatment option for pediatric venous thromboembolism. Children aged 1 to < 12 years were given dabigatran etexilate in an open-label, single-arm study. The pharmacokinetic-pharmacodynamic relationship was similar to that seen in adult patients. There were no serious adverse events, bleeding events or recurrent venous thromboembolism. SUMMARY: Background The current standard-of-care treatments for pediatric venous thromboembolism (VTE) have limitations. Dabigatran etexilate (DE), a direct thrombin inhibitor, may offer an alternative therapeutic option. Objectives To assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of a DE oral liquid formulation (OLF) in pediatric patients with VTE. Patients/Methods Patients who had completed planned treatment with low molecular weight heparin or oral anticoagulants for VTE were enrolled in two age groups (2 to < 12 years and 1 to < 2 years), and received a DE OLF based on an age-adjusted and weight-adjusted nomogram. Originally, patients were to receive a DE OLF twice daily for 3 days, but the protocol was amended to a single dose on day 1. The primary endpoints were pharmacokinetics/pharmacodynamics-related: plasma concentrations of DE and its metabolites; activated partial thromboplastin time (APTT), ecarin clotting time (ECT), and dilute thrombin time (dTT); and pharmacokinetic (PK)-pharmacodynamic (PD) correlation. Safety endpoints included incidence rates of bleeding events and all other adverse events (AEs). Results Eighteen patients entered the study and received the DE OLF (an exposure equivalent to a dose of 150 mg twice daily in adults). The projected steady-state dabigatran trough concentrations were largely comparable between pediatric patients and adults. The PK/PD relationship was linear for ECT and dTT, and non-linear for APTT. No serious or severe AEs, bleeding events, or recurrent VTEs were reported. Mild AEs were reported in three patients in the single-dose group (screening period) and in one patient in the multiple-dose group (on-treatment period). Conclusion The current study supports the further evaluation of DE OLFs in pediatric patients with VTE.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Halton JML, Albisetti M, Biss B, et al. Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability. J Thromb Haemost. 2017. PMID: 28921890. doi:10.1111/jth.13847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。